NCT03587714 is a clinical trial of HCV RT-PCR in Hepatitis C, sponsored by Assiut University.

Who is sponsoring NCT03587714?

NCT03587714 is sponsored by Assiut University.

What drugs are being tested in NCT03587714?

Interventions in NCT03587714: HCV RT-PCR.

What condition does NCT03587714 study?

NCT03587714 studies Hepatitis C.

Is NCT03587714 still recruiting?

NCT03587714 is currently completed. Last updated 16 July 2018.

Last reviewed 2018-07-16 · How we verify

NCT03587714

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients

Completed Last updated 16 July 2018

What this trial tests

trial testing HCV RT-PCR in Hepatitis C in 800 participants. Completed in 1 March 2018.

Timeline

1 January 2017

Primary endpoint
1 December 2017

1 March 2018

Quick facts

Lead sponsor	Assiut University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	800
Start date	1 January 2017
Primary completion	1 December 2017
Estimated completion	1 March 2018
Sites	1 location across Egypt

Drugs / interventions tested

HCV RT-PCR

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Assiut University

Who can join

Adults 20 to 80, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. In 2015, the prevalence of HCV RNA was found to be 7.0%.(1) The prevalence of HCV was studied in Rheumatoid arthritis in few studies(2,3), but to our knowledge, no previous work studied it in other rheumatologic diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03587714 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 16 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03587714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing